Abstract

Simple SummaryFanconi anemia (FA) is a genetic disorder that is characterized by bone marrow failure (BMF), developmental abnormalities, and predisposition to cancer. In this review, we present an overview of both canonical (regulation of interstrand cross-links repair, ICLs) and noncanonical roles of FA proteins. We divide noncanonical alternative functions in two types: nuclear (outside ICLs such as FA action in replication stress or DSB repair) and cytosolic (such as in mitochondrial quality control or selective autophagy). We further discuss the involvement of FA genes in the predisposition to develop different types of cancers and we examine current DNA damage response-targeted therapies. Finally, we promote an insightful perspective regarding the clinical implication of the cytosolic noncanonical roles of FA proteins in cancer predisposition, suggesting that these alternative roles could be of critical importance for disease progression.Fanconi anemia (FA) is a clinically and genetically heterogeneous disorder characterized by the variable presence of congenital somatic abnormalities, bone marrow failure (BMF), and a predisposition to develop cancer. Monoallelic germline mutations in at least five genes involved in the FA pathway are associated with the development of sporadic hematological and solid malignancies. The key function of the FA pathway is to orchestrate proteins involved in the repair of interstrand cross-links (ICLs), to prevent genomic instability and replication stress. Recently, many studies have highlighted the importance of FA genes in noncanonical pathways, such as mitochondria homeostasis, inflammation, and virophagy, which act, in some cases, independently of DNA repair processes. Thus, primary defects in DNA repair mechanisms of FA patients are typically exacerbated by an impairment of other cytoprotective pathways that contribute to the multifaceted clinical phenotype of this disease. In this review, we summarize recent advances in the understanding of the pathogenesis of FA, with a focus on the cytosolic noncanonical roles of FA genes, discussing how they may contribute to cancer development, thus suggesting opportunities to envisage novel therapeutic approaches.

Highlights

  • Fanconi anemia (FA) is a rare genetic disorder caused by an alteration of the genome integrity that affects one in every 100,000 births [1]

  • The former typically originates from unresolved D-loops that are not processed through Holliday junction intermediates, while the latter is a telomere maintenance mechanism used by cancers that do not reactivate telomerase expression [30]

  • Using isogenic cells derived from patients and from nullizygous mice carrying inactivating mutations in the FANCC gene, Pang and colleagues discovered that FANCC protects against proinflammatory cytokine-induced cell death by interacting with signal transducer and activator of transcription 1 (STAT1) [85] and stress-inducible heat shock protein 70 (HSPA1A) [86]

Read more

Summary

Introduction

Fanconi anemia (FA) is a rare genetic disorder caused by an alteration of the genome integrity that affects one in every 100,000 births [1]. It is defined by a very heterogeneous genetic and clinical picture, involving one or more hematopoietic cell lineages and typically characterized by a wide spectrum of congenital somatic abnormalities (including short stature), bone marrow failure (BMF) and the predisposition to develop both hematological and solid malignancies [2]. Interact with cytochrome P450 to respond oxidative damage; mitophagy effector through PARKIN interaction; virophagy mediator. Interact with cytochrome P450 to respond oxidative damage; involved in mitochondria morphology regulation. E3 ubiquitin ligase of the β-Catenin ubiquitination; involved in mitophagy; virophagy mediator

Canonical Role of FA Proteins
Noncanonical Role of FA Proteins
FA and Replication Stress
FA in DSB Repair
FA and Transcription-Replication Conflicts
Emerging Cytosolic Roles of FA Proteins
Mitochondria
Endocrinopathies
Inflammation
Virophagy
Hematopoietic Defects in FA Patients
FA Proteins and Cancer Predisposition
DNA Damage Response-Targeted Therapies in FA Patients
Findings
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call